Thiazolidinedione therapy for managing metabolic syndrome

American Family Physician

Volumn 82, Issue 12, 2010, Pages 1553-1554

  Geurin, Michael D ^a   Anna, Leilani St ^b  

^a Montana Family Medicine Residency   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; LIGAND;

BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; EVIDENCE BASED MEDICINE; GENETIC HETEROGENEITY; HUMAN; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MONOTHERAPY; NOTE; OUTCOME ASSESSMENT; SIDE EFFECT; WAIST CIRCUMFERENCE; REVIEW; TREATMENT OUTCOME;

HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; METABOLIC SYNDROME X; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 79952276940     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Note

References (10)

1. Cao Z, Zhou YJ, Zhao YX, Liu YY, Guo YH, Cheng WJ. Rosiglitazone could improve clinical outcomes after coronary stent implantation in nondiabetic patients with metabolic syndrome. Chin Med J (Engl). 2006;119(14):1171-1175.
2. Lester JW, Fernandes AW. Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome. Int J Clin Pract. 2005;59(2):134-142.
3. Norris SL, Carson S, Roberts C. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis. Curr Diabetes Rev. 2007;3(2):127-140.
4. Einhorn D, Aroda VR, Henry RR. Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol Metab Clin North Am. 2004;33(3):595-616.
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
6. Grundy SM, Cleeman JI, Merz CN, et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation. 2004; 110(6):763].
7. Circulation. 2004;110(2):227-239.
8. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in JAMA. 2003;290(2):197].
9. JAMA. 2003;289(19):2560-2572.
10. Fletcher B, Berra K, Ades P, et al.; Council on Cardiovascular Nursing; Council on Arteriosclerosis, Thrombosis, and Vascular Biology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Nutrition, Physical Activity, and Metabolism; Council on Stroke; Preventive Cardiovascular Nurses Association. Managing abnormal blood lipids: a collaborative approach. Circulation. 2005;112(20):3184-3209.